These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 7554807

  • 21. Tentative interpretive criteria for disk diffusion susceptibility testing of sparfloxacin.
    Fuchs PC, Barry AL, Pfaller MA.
    J Clin Microbiol; 1993 Aug; 31(8):2236-7. PubMed ID: 8396592
    [Abstract] [Full Text] [Related]

  • 22. In vitro activity of sparfloxacin and three other fluoroquinolones against methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis.
    Smith KR, Cobbs CG.
    Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):55-8. PubMed ID: 1314175
    [Abstract] [Full Text] [Related]

  • 23. In vitro activity of sparfloxacin (CI-978), a new broad-spectrum fluoroquinolone.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Chemotherapy; 1992 Jan; 38(2):99-106. PubMed ID: 1317282
    [Abstract] [Full Text] [Related]

  • 24. Interpretive criteria for CI-960, fleroxacin and temafloxacin susceptibility tests with Haemophilus influenzae.
    Barrett MS, Jones RN.
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):462-5. PubMed ID: 1330563
    [Abstract] [Full Text] [Related]

  • 25. Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae.
    Jones RN, Barrett MS, Biedenbach DJ.
    Diagn Microbiol Infect Dis; 1994 Jun; 19(2):93-9. PubMed ID: 7805362
    [Abstract] [Full Text] [Related]

  • 26. Fluoroquinolone (Lomefloxacin) International Surveillance Trial: a report of 30 months of monitoring in vitro activity.
    Jones RN.
    Am J Med; 1992 Apr 06; 92(4A):52S-57S. PubMed ID: 1316072
    [Abstract] [Full Text] [Related]

  • 27. Activity of nadifloxacin against methicillin-resistant Staphylococcus aureus isolated from skin infections: comparative study with seven other fluoroquinolones.
    Nishijima S, Nakagawa M, Tsuboi N, Akamatsu H, Horio T, Fujita M, Kawabata S.
    J Int Med Res; 1996 Apr 06; 24(1):12-6. PubMed ID: 8674789
    [Abstract] [Full Text] [Related]

  • 28. In vitro activity of lomefloxacin, a difluorinated quinolone, compared with other antimicrobials.
    Qadri SM, Lee GC, Ellis ME.
    Chemotherapy; 1991 Apr 06; 37(3):166-74. PubMed ID: 1889304
    [Abstract] [Full Text] [Related]

  • 29. CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria.
    Fuchs PC, Barry AL, Jones RN, Thornsberry C, Ayers LW, Gavan TL, Gerlach EH.
    Diagn Microbiol Infect Dis; 1987 Mar 06; 6(3):185-92. PubMed ID: 3471371
    [Abstract] [Full Text] [Related]

  • 30. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
    Jones RN, Johnson DM, Biedenbach DJ, Marshall SA.
    Diagn Microbiol Infect Dis; 1995 Nov 06; 23(3):123-7. PubMed ID: 8849658
    [Abstract] [Full Text] [Related]

  • 31. Lomefloxacin: microbiologic assessment and unique properties.
    Mayer KH, Ellal JA.
    Am J Med; 1992 Apr 06; 92(4A):58S-62S. PubMed ID: 1316073
    [Abstract] [Full Text] [Related]

  • 32. In vitro activity of lomefloxacin against multiply resistant Pseudomonas aeruginosa, Enterobacter cloacae, and Staphylococcus epidermidis.
    DiVincenzo CA, Shatzer KL, Venezio FR.
    Diagn Microbiol Infect Dis; 1989 Apr 06; 12(3 Suppl):13S-16S. PubMed ID: 2507220
    [Abstract] [Full Text] [Related]

  • 33. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK, Nisha AK, Bhattacharya SS, Ramamoorthy U, Lal HM.
    Indian J Med Res; 1990 May 06; 91():182-4. PubMed ID: 2397938
    [Abstract] [Full Text] [Related]

  • 34. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM, Ueno Y, Burns JJ, Almodovar E, Rabea N.
    Drugs Exp Clin Res; 1992 May 06; 18(8):311-7. PubMed ID: 1338041
    [Abstract] [Full Text] [Related]

  • 35. Disk diffusion interpretive criteria for fusidic acid susceptibility testing of staphylococci by the National Committee for Clinical Laboratory Standards method.
    Coutant C, Olden D, Bell J, Turnidge JD.
    Diagn Microbiol Infect Dis; 1996 May 06; 25(1):9-13. PubMed ID: 8831039
    [Abstract] [Full Text] [Related]

  • 36. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods. The Quality Control Study Group.
    Jones RN, Kugler KC, Erwin ME, Biedenbach DJ, Beach ML, Pfaller MA.
    Diagn Microbiol Infect Dis; 1999 Apr 06; 33(4):247-53. PubMed ID: 10212751
    [Abstract] [Full Text] [Related]

  • 37. A multicenter study on the comparative in vitro activity of fleroxacin and three other quinolones: an interim report from 27 centers.
    Beskid G, Prosser BL.
    Am J Med; 1993 Mar 22; 94(3A):2S-8S. PubMed ID: 8383919
    [Abstract] [Full Text] [Related]

  • 38. Lomefloxacin activity against 2,813 clinical isolates: a collaborative study at three medical centers in Brazil.
    Magalhaes M, Trabulsi LR, Montelli AC.
    Diagn Microbiol Infect Dis; 1989 Mar 22; 12(3 Suppl):35S-39S. PubMed ID: 2791496
    [Abstract] [Full Text] [Related]

  • 39. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli isolates.
    Tavío MM, Vila J, Ruiz J, Ruiz J, Martín-Sánchez AM, Jiménez de Anta MT.
    J Antimicrob Chemother; 1999 Dec 22; 44(6):735-42. PubMed ID: 10590273
    [Abstract] [Full Text] [Related]

  • 40. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
    Edwards R, Kanematsu M, Greenwood D.
    J Antimicrob Chemother; 1988 Dec 22; 22(6):885-90. PubMed ID: 3243736
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.